TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Alpha Teknova, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.80−0.28 (-3.95%)
Close on Oct 19, 2026
- Market cap
- $364.72M
- P/E (TTM)
- –
- Dividend yield
- –
Alpha Teknova, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lab Essentials [Member] | $32.71M | $31.32M | $31.04M | $31.04M | $29.89M | $29.73M | $28.88M | $28.75M | $28.87M | $28.81M | $28.80M | $29.05M | 74.9% | +9.5% |
| Clinical Solutions [Member] | $9.00M | $8.63M | $7.65M | $6.78M | $7.04M | $6.54M | $7.10M | $6.13M | $4.76M | $6.85M | $6.74M | $6.63M | 20.6% | +27.9% |
| Other [Member] | $1.99M | $1.85M | $1.83M | $1.99M | $2.00M | $1.98M | $1.77M | $1.47M | $1.32M | $1.20M | $1.15M | $1.03M | 4.5% | -0.7% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $41.42M | $39.54M | $38.25M | $37.65M | $36.87M | $36.32M | $35.92M | $34.53M | $33.30M | $35.14M | $35.00M | $35.24M | 94.8% | +12.3% |
| International [Member] | $2.28M | $2.26M | $2.27M | $2.16M | $2.05M | $1.93M | $1.83M | $1.82M | $1.64M | $1.71M | $1.68M | $1.47M | 5.2% | +11.1% |
From the segment and revenue-disaggregation notes of Alpha Teknova's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.